You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 268 A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101)

Citation Tools

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials completed
268 A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Berton-Rigaud D, Vergote I, Pautier P, et al
268 A phase 1 study of retifanlimab (INCMGA00012), a PD-1 inhibitor, in patients with advanced solid tumors: preliminary results in recurrent MSI-high or dMMR endometrial cancer (POD1UM-101)
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0268